AZ's MedImmune sues Abbott over non-development and $50m payment deficit for RSV antibodies
This article was originally published in Scrip
Executive Summary
Another drug development pact has resulted in a heated dispute – as AstraZeneca subsidiary MedImmune has sued Abbott after the Illinois company unilaterally halted seeking approval of the respiratory syncytial virus treatment motavizumab outside the US. Exacerbating the dispute, Abbott also claims that the absence of development for motavizumab means it can reduce what it pays for exclusive ex-US rights to distribute MedImmune's first-generation RSV product, Synagis (palivizumab). MedImmune disagrees.